Studying DNA changes and biological age in preventing chronic diseases in Kazakhstan
Examines DNA analysis and biological age in adults at risk of chronic diseases.
Key facts
- Who runs it
- Asfendiyarov Kazakh National Medical University
- Where
- Almaty, KazakhstanSee the site
- Trial code
- Registry title
- Epigenetics and NCD Prevention in Kazakhstan: Personalized Approaches and Biological Age Prediction
- Status
- Recruiting
- People taking part
- 6,720 people, planned
- Started
- 3 Mar 2025
- Expected to end
- 31 Dec 2026
- Type of study
- Observational
- Treatments tested
- Genetic: DNA analysis
- Record updated
- 11 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 69 who live in 17 regions of Kazakhstan and are willing to take part.
- Age
- 18 to 69 years
- Sex
- All sexes can join.
Main reasons for not taking part
- Under 18 years old or over 69 years old
- Does not give informed consent
- Does not complete the data collection procedures
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Adults aged 18 to 69 years
- Residents of 17 regions of Kazakhstan
- Willingness to participate and provide informed consent
Who cannot take part
- Failure to provide informed consent or incomplete participation in data collection procedures
- Age less than 18 years old or over 69 years old
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 69 years old?
Where in Kazakhstan
- Asfendiyarov Kazakh National Medical UniversityAlmaty, KazakhstanContact: Ildar Fakhradiyev, PhDTaking people
About the trial
What the trial wants to find out
This study aims to enhance personalized and preventive care for non-communicable diseases (NCDs) in Kazakhstan by examining epigenetic factors, predicting biological age and reproductive function using machine learning, and developing health improvement recommendations.
The group in the trial
- The study includes 1 cohort divided into 4 age subgroups.
The study follows a multistage cluster sampling design with age and gender stratification. A total of 1 cohorts have been identified, further divided into 4 age subgroups: 1. 18-29 years 2. 30-44 years 3. 45-59 years 4. 60-69 years Each age group is designed to have an equal distribution of men and women, ensuring gender balance across all subgroups.
Treatment: Genetic: DNA analysis
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Epigenetics and Prevention of Non-communicable Diseases in Kazakhstan: a Personalized Approach and Biological Age Prediction
- Plain-language title
- Studying DNA changes and biological age in preventing chronic diseases in KazakhstanGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06953180, who can take part
- Publications
- Age-Metabolic Profile of Lower Serum Estradiol Among Women in Kazakhstan: A Large National Survey-Based Analytical Study.International journal of environmental research and public health, 2026
- Record updated
- 11 July 2025